Pharvaris NV (FRA:9EN) Net Margin %: 0.00% (As of Mar. 2026)


FRA:9EN Pharvaris NV FRA:9EN
33 GF Score
Price €30.70
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV Net Margin %?

Pharvaris NV FRA:9EN -1.76% 33 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:9EN with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 939 Biotechnology companies, Pharvaris NV ranks worse than 106496.17% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Pharvaris NV's Net Income for the three months ended in Mar. 2026 was €-39.20 Mil. Pharvaris NV's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Pharvaris NV's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Pharvaris NV's Net Margin % or its related term are showing as below:


FRA:9EN's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

Pharvaris NV  (FRA:9EN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Pharvaris NV Net Margin % Related Terms

Pharvaris NV Net Margin % Historical Data

* Premium members only.

The historical data trend for Pharvaris NV's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharvaris NV Net Margin % Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pharvaris NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:9EN vs BHVN, NRIX, VCEL: Net Margin % Comparison

For the Biotechnology subindustry, Pharvaris NV's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's Net Margin % distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's Net Margin % falls into.


FRA:9EN
33GF Score
Pharvaris NV FRA:9EN
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Pharvaris NV's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-175.699/0
= %

Pharvaris NV's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-39.201/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Pharvaris NV (FRA:9EN) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Pharvaris NV and its competitors. According to the industry distribution chart, Pharvaris NV ranks #999999 out of 939 companies in the Biotechnology industry.
Is Pharvaris NV's Net Margin % too high?
Pharvaris NV's current Net Margin % is 0.00%. Based on the distribution chart, Pharvaris NV ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pharvaris NV has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's Net Margin % compare to BHVN and NRIX?
According to the Biotechnology industry distribution chart, Pharvaris NV ranks #999999 out of 939 companies for Net Margin %. This places Pharvaris NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Pharvaris NV and its competitors. Pharvaris NV's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (FRA:9EN) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Pharvaris NV's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Pharvaris NV (FRA:9EN), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges PHVS:USA
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
33GF Score

Get the complete analysis for FRA:9EN

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.70
Price